A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab

scientific article published on 27 March 2019

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1113049507
P356DOI10.1186/S12967-019-1847-X
P932PMC publication ID6437908
P698PubMed publication ID30917841

P50authorPatrizia ViciQ28833492
Paolo MarchettiQ56815155
Raffaele GiustiQ89096158
P2093author name stringLidia Strigari
Bruna Cerbelli
Marco Mazzotta
Laura Pizzuti
Andrea Botticelli
Massimiliano Salati
Michela Roberto
Marianna Nuti
Federica Mazzuca
Francesca Romana Di Pietro
Ilaria Grazia Zizzari
P2860cites workNivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerQ29620902
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerQ29620913
Hepatic T cells and liver toleranceQ35038298
Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung CancerQ38761172
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung CancerQ38975751
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialQ40163779
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.Q46573013
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancerQ47101079
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life dataQ47287282
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.Q47840963
Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastasesQ50161502
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.Q52586557
Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution.Q54962510
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial.Q55400478
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upQ57051777
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?Q58799410
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesQ60142201
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCQ88973544
Review of checkpoint immunotherapy for the management of non-small cell lung cancerQ90931697
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 BlockadeQ91392607
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectnomogramQ721129
immunotherapyQ1427096
nivolumabQ7041828
P304page(s)99
P577publication date2019-03-27
P1433published inJournal of Translational MedicineQ15716664
P1476titleA nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
P478volume17

Reverse relations

cites work (P2860)
Q92137062A prognostic nomogram for neuroblastoma in children
Q98177668Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1

Search more.